EdiGene Revenue and Competitors
Estimated Revenue & Valuation
- EdiGene's estimated annual revenue is currently $2.2M per year.
- EdiGene's estimated revenue per employee is $38,750
- EdiGene's total funding is $179.7M.
Employee Data
- EdiGene has 57 Employees.
- EdiGene grew their employee count by -28% last year.
EdiGene's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | COO | Reveal Email/Phone |
3 | CTO | Reveal Email/Phone |
4 | Senior Director Quality and Production | Reveal Email/Phone |
5 | US Site Head | Reveal Email/Phone |
EdiGene Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $10.2M | 131 | -2% | $312.8M | N/A |
#2 | $4.2M | 54 | N/A | N/A | N/A |
#3 | $2.2M | 57 | -28% | $179.7M | N/A |
#4 | $23.9M | 309 | -14% | N/A | N/A |
#5 | $0.9M | 12 | 0% | N/A | N/A |
#6 | $1.7M | 22 | 0% | N/A | N/A |
#7 | $19M | 245 | -14% | N/A | N/A |
#8 | $9.4M | 121 | 3% | N/A | N/A |
What Is EdiGene?
EdiGene is a clinical-stage biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA.
keywords:N/A
$179.7M
Total Funding
57
Number of Employees
$2.2M
Revenue (est)
-28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EdiGene News
By leveraging EdiGene's systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our...
"By leveraging EdiGene's systematic research on related genes responding to specific targeted therapy for advanced colorectal cancer, and our...
Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation. The Series B+ round roped in new investors ...
Premium Chinese novel gene-editing platform EdiGene Inc has raised 450 million yuan ($67 million) in its Series B round funding led by Chinese healthcare industry focused private equity fund 3H Health, according to a company statement on October 13. Continue reading this story with a subscript ...
EdiGene, Inc., a Beijing, China-based developer of genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, completed an RMB 450 million (approximately USD 67 million) Series B financing. The round was led by 3H Health Investment wit ...
Other Companies in Beijing
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.4M | 57 | -2% | N/A |
#2 | $11M | 58 | 12% | N/A |
#3 | $8M | 61 | -3% | N/A |
#4 | $8.4M | 62 | 9% | N/A |
#5 | $9.2M | 62 | 13% | N/A |